PRESS RELEASES
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania.
King of Prussia, PA – July 01, 2022 – Seed Therapeutics has completed construction of a state of the art 10,000 square foot innovation and research center including 7,000 square feet of cutting edge lab space at 411 Swedeland Road in King of Prussia, Pennsylvania.
LATEST PRESS RELEASES
Nature: Protein degraders push into novel target space
Nature: Protein degraders push into novel target space Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory.
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head...
SEED Therapeutics Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of...